Menu

Bacteria-Treated Mosquitoes Released in More Locations

Infected with Wolbachia, the insects are expected to reduce the spread of dengue and Zika. But scientists say the approach may have limitations.

Jan 17, 2017
Kerry Grens

WIKIMEDIA, SCOTT O'NEILLAedes mosquitoes infected with the bacterium Wolbachia can slow the spread of dengue and Zika viruses carried by the insects, and several nations have launched early programs to deploy the mosquitoes, while others plan to introduce or expand their deployment.

Earlier this month (January 6), Eliminate Dengue announced its intention to expand from field trials to pilot sites in Nha Trang, Vietnam this coming March, a few months after the organization unveiled plans to increase the release of bacteria-treated mosquitoes in Colombia and Brazil. “The release of mosquitos with Wolbachia has been implemented on a trial basis in the city’s Tri Nguyen island, and has proved effective,” according to Xinhua, “no dengue fever outbreaks have been reported in the island.”

In December, Radio New Zealand reported that the island of New Caledonia would also release Wolbachia-laced mosquitoes. Indonesia and Australia, too, are expanding the number of sites where researchers are releasing bacteria-bearing mosquitoes.

Eliminate Dengue’s approach reduces the transmissibility of the virus among mosquitoes. Another tack involving Wolbachia, led by the Sun Yat-Sen-Michigan State University Joint Center of Vector Control for Tropical Disease, causes sterility in male mosquitoes, thereby potentially reducing disease by cutting vector populations.

Last month, CNN reported that researchers had released these mosquitoes on a Chinese island. “So far, members of [Zhiyong] Xi's team claim that they have suppressed the mosquito population on the island by a whopping 96%, but scientists have questioned whether he will be able to scale up his island experiment in larger areas,” according to CNN. Xi said he wants to expand to more populated areas and to Mexico.

In the United States, a company rearing Wolbachia-infected sterile mosquitoes similar to those released by Xi’s team received permission from federal authorities in September to release its insects in California and Florida.

But there may be limitations to Wolbachia’s efficacy. This month (January 5), one study in PLOS Pathogens concluded that certain strains of the bacteria don’t work well at high temperatures in reducing transmission of the virus between mosquitoes. “Since mosquito larvae experience extreme temperatures in their natural habitat, our results have implications for current and future releases of Wolbachia-infected mosquitoes and highlight the need for further investigation into alternative strains of Wolbachia,” the authors wrote.

“Although it was alarming to see that Wolbachia is vulnerable to high temperature, it is promising that other strains are more robust,” said lead author Perran Ross, a graduate student at the University of Melbourne, in a press release. “These strains are also effective at blocking viruses.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.